GENE ONLINE|News &
Opinion
Blog

Biomarin Pharmaceuticals
Will Breakthrough Therapy Lead the Way? An Overview of the Approved Gene and Cell Therapies for 2022
2023-01-13
FDA Accepts Resubmission of BioMarin’s Gene Therapy Two Years After Rejection
2022-10-13
Homology Medicines Joins Biomarin in Gene Therapy Clinical Hold
2022-02-22
ARM 2022: Industry Briefs on Cell and Gene Therapies
2022-01-17
BioMarin’s Dwarfism Drug Garners FDA Nod Amidst Concerns Over Threat to Dwarf Pride
2021-11-21
The Transformative Potential of Gene Therapies for Hemophilia
2021-04-08
R&D
BioMarin Collaborates with Canadian Biotech for AI-based Drug Discovery
2020-11-22
FDA Rejects BioMarin Pharmaceuticals’ Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A
2020-08-20
LATEST
Healthcare+ Expo Taiwan 2024 To Become A Global Trade Fair With 600+ Companies Attending
2024-11-29
Cracking the Code: How Genetics Shapes Strength, Power, and Speed in Sports
2024-11-27
Shared Expertise, Shared Vision: Biotech Powerhouses Drive Innovation in This Billion-Dollar Market
2024-11-27
MIRDC Hosts Seminar Featuring Diverse Applications of Plasma Sterilization Technology
2024-11-26
How Minaris is Tackling the Scalability Challenge in Cell and Gene Therapy: A Conversation with CEO, Dr. Hiroto Bando
2024-11-26
PuriBlood Breaks into Brazil: Partners with ABHH and Cromo to Conquer Latin America’s Largest Blood Market
2024-11-26
Merck’s Multi-Billion-Dollar KEYTRUDA Levels Up with Novel Subcutaneous Delivery, Matching IV Efficacy
2024-11-22
EVENT
2024-12-05
8th Healthcare Expo Taiwan
Taipei, Taiwan
Scroll to Top